In 2015, Cuba Business Report, claimed that there were a variety of pharmaceutical anticancer agents in various stages of development there, including:

• CIMAVAX-EGF, which also has clinical trials underway in Canada, the UK, Malaysia and China.


• Racotumomab, which reported some success in a Cuban clinical trial, published in the Journal of the American Association for Clinical Research.


• Theraloc (nimotuzumab), developed by the Center for Molecular Immunology (CIM) in Havana, Cuba, has undergone global clinical trials and is available for various therapies to combat esophageal cancer, glioma, neck and head cancer in India, Japan, China, and some Latin America and Eastern European countries. It has orphan drug status in the U.S.

Roswell's Dr. Kevin Lee had been informally talking with CIM about the vaccine since 2011, according to the New York Times.



Cuban scientists began their research in the 1990s. Cubans have been able to get CIMAVAX-EGF for free since that year, noted the paper.

"This is a day we have been working toward for many years,” Agustín Lage, director of CIM, stated. “Our partnership with Roswell Park will allow us to learn things about our vaccine faster than what we could achieve working on our own, and we believe it is the best and quickest path for helping a great number of people both in Cuba and the U.S.”

Back to HCB News

Rad Oncology Homepage